602.889.9700
opportunity analysis

Lytham Partners Services

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time.

No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on this website and/or publications or presentations released by Lytham to the public through this website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned on this website or in Lytham's publications or presentations, Lytham strongly encourages and recommends consultation with a registered securities representative. This website and/or publications or presentations released by Lytham to the public through this website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will.  Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed in this website and/or publications or presentations released by Lytham are subject to change without notice.

Compensation Information: Lytham is compensated by its clients for providing certain investor relations services, such as consulting, preparation of collateral materials, arranging non-deal roadshows, and other investor relations related services.  The compensation provided to Lytham is as follows: Abaxis compensates Lytham at a rate of $3,850 per month. AZZ incorporated compensates Lytham at a rate of $4,500 per month. Eastside Distilling compensates Lytham at a rate of $4,000 per month and has 6,979 restricted shares. EnSync compensates Lytham at a rate of $7,500 per month. ImmuCell compensates Lytham at a rate of $10,000 per quarter.  ImmunoCellular Therapeutics, Ltd. compensates Lytham at a rate of $7,500 per month.  InfuSystem compensates Lytham at a rate of $7,500 per month as well as the ability to vest in 40,000 options based on achieving certain criteria, including increased research coverage, conference invitations, increased shareholder ownership and stock price. INVO Bioscience compensates Lytham at a rate of $500 per month as well as 20,000 restricted shares per month. Lytham currently owns 1.5M restricted shares of INVO Bioscience. MGC Diagnostics compensates Lytham at a rate of $7,500 per month. MamaMancini's compensates Lytham at a rate of $9,000 per quarter. Misonix compensates Lytham at a rate of $5,000 per month. Moleculin Biotech, Inc. compensates Lytham at a rate of $7,500 per month. SenesTech compensates Lytham at a rate of $7,500 per month and currently has options to acquire 5,250 shares. S&W Seed Company compensates Lytham at a rate of $6,000 per month. Trinity Biotech compensates Lytham at a rate of $4,000 per month. VerifyMe, Inc. compensates Lytham at a rate of $1,500 per month and 40,000 restricted shares per month for the first six months. The following six months VerifyMe compensates Lytham at a rate of $5,500 per month and 13,500 restricted shares per month. Clients reimburse Lytham Partners for certain specified expenses.

Information Sources and Forward-Looking Statements: The information contained in this website and/or publications or presentations about Lytham's clients was obtained from materials available to the general public, including the clients' filings with the SEC, documents included on the client's websites, information provided by the client or from other publicly available sources deemed reliable by Lytham.  Lytham does not represent or guarantee the accuracy or completeness of this information. This information is subject to change without notice and Lytham assumes no responsibility to update the information, except as required by law. The information contained in this website and/or publications or presentations about Lytham's clients may contain "forward‐looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("Reform Act"), as well as Regulation FD.  These statements may involve risks and uncertainties that could cause actual results to differ materially from the forward‐looking statements. Factors which could cause or contribute to such differences are detailed in the company's public filings with the United States Securities and Exchange Commission, if available. Forward‐looking statements speak only as of the date the statement was made. Neither the company nor Lytham undertakes, and specifically disclaims, any obligation to update any forward‐looking statements. The company claims the protection of the safe‐harbor for forward‐looking statements contained in the Reform Act. Any performance data quoted represents past performance of the company. There is no guarantee of comparable future results; current performance may be higher or lower.